A recent Psychiatry digest,
as sent to subscribers

Study Type: Insufficient information — abstract content not provided; cannot determine study type or findings.

Key Question: What are the patterns of use and misuse of GLP-1 receptor agonists (e.g., semaglutide, liraglutide) among individuals with eating disorders?

Key Findings:

• Abstract text was not supplied; specific findings, effect sizes, or prevalence data cannot be extracted.
• The title suggests the study examines both therapeutic use and potential misuse/diversion in an eating disorder population.
• No further detail available from the information provided.

Clinical Relevance: Directly relevant to UK psychiatry practice given widespread NHS prescribing of GLP-1 agonists for obesity and emerging concerns about their potential for misuse in patients with restrictive or purging eating disorders.

Limitations: Abstract not provided; full assessment of methodology and limitations is not possible.

Study Type: RCT (double-blind, single-centre)

Key Question: Does functional connectivity neuroimaging-guided targeting of accelerated TMS produce superior antidepressant outcomes compared to standard scalp-based targeting in treatment-resistant depression?

Key Findings:

• Connectivity-based targeting produced a greater median MADRS reduction than scalp-based targeting (24 vs 18 points; p=0.02) at one month post-treatment
• Effect size was moderate-to-large (Cohen's d=0.8, 95% CI 0.26–1.54), with a number needed to scan of 5
• Individualised targets were reproducible within participants (4.47mm split-half distance) but meaningfully distinct between participants (12.97mm), supporting the biological rationale for personalisation

Clinical Relevance: As NHS services evaluate TMS pathways for treatment-resistant depression, this trial suggests neuroimaging-guided targeting may meaningfully enhance outcomes, informing future commissioning and cost-effectiveness decisions.

Limitations: Small sample (n=40) at a single US academic centre limits generalisability; a larger confirmatory trial is explicitly acknowledged as necessary.

Study Type: Mega-analysis with individual participant data (IPD) and accompanying meta-analysis

Key Question: Are specific brain neurometabolites measurable by MRS associated with antipsychotic non-response in psychosis?

Key Findings:

• Antipsychotic non-responders showed significantly elevated medial frontal glutamate (Glass Δ=0.21), glutamate+glutamine (Δ=0.29), choline (Δ=0.22), and myo-inositol (Δ=0.35) compared to responders (n=1,189 across 18 studies)
• Elevated medial frontal glutamate+glutamine predicted non-response prospectively in first-episode psychosis (Δ=0.41), suggesting potential pre-treatment biomarker utility
• Myo-inositol elevations were most pronounced in treatment-resistant schizophrenia (Δ=0.64), implicating neuroinflammatory pathways

Clinical Relevance: These findings support neuroimaging-based stratification of treatment resistance at first episode, directly relevant to early clozapine decision-making pathways in NHS Early Intervention in Psychosis services.

Limitations: Effect sizes are small-to-moderate and MRS is not yet clinically scalable across NHS settings, limiting immediate translational application.

Study Type: Commentary / regulatory case analysis

Key Question: How did the FDA evaluate and ultimately approve gepirone ER for major depressive disorder despite predominantly negative trial evidence?

Key Findings:

• Of 13 preapproval trials, only 2 acute treatment trials were judged positive; gepirone ER failed to beat placebo in the remainder, and showed statistical inferiority to active comparators in 3 trials.
• The FDA rejected the application four times (1999–2007) and its own Advisory Committee voted against approval in 2015; approval was nonetheless granted following senior FDA leadership intervention.
• Authors argue current regulations permit "regulatory flexibility" prioritising statistical over clinical significance, and that product labelling omits negative trials, limiting informed prescribing.

Clinical Relevance: UK clinicians evaluating antidepressant evidence should be aware that FDA-approved status does not guarantee a robust evidence base; similar publication/approval biases may affect MHRA-licensed agents.

Limitations: Single-drug case analysis limits generalisability to broader regulatory patterns.

Study Type: Commentary/Editorial

Key Question: How might the new CMS (US Medicare/Medicaid) reimbursement framework for AI-delivered behavioural health interventions reshape clinical practice and payment structures?

Key Findings:

• CMS has introduced a payment model specifically enabling reimbursement for AI-delivered behavioural health care, representing a significant policy shift in the US
• The authors discuss implications for clinical accountability, quality oversight, and the integration of AI tools within existing care pathways
• Concerns are raised regarding equitable access and the evidence base required to justify AI-delivered interventions under this framework

Clinical Relevance: Although US-specific, this commentary is directly relevant to UK clinicians as NHS England and NICE are actively developing frameworks for AI-enabled mental health tools; understanding CMS precedents may inform UK commissioning and regulatory approaches.

Limitations: As an editorial, no primary data are presented; conclusions reflect author opinion rather than empirical evidence.

Study Type: Systematic review and meta-analysis (with network-based neuroimaging analysis)

Key Question: Are there shared and disorder-specific patterns of grey matter volume (GMV) reduction across MDD, bipolar disorder, and schizophrenia, and can these be mapped onto functional brain networks?

Key Findings:

• Across 221 VBM studies (10,485 patients; 12,128 controls), transdiagnostic GMV reductions were consistently identified in the medial prefrontal cortex and superior temporal gyrus
• Schizophrenia showed greater limbic/paralimbic and temporoparietal junction atrophy versus MDD; the ventrolateral PFC was a shared disease epicenter across all three diagnoses
• The precuneus acted as a common structural buffer, with visual and dorsal attention networks showing the strongest buffering effects

Clinical Relevance: These transdiagnostic neuroimaging findings may support future biomarker-informed diagnostic frameworks relevant to UK services moving towards stratified psychiatry.

Limitations: VBM meta-analyses are constrained by heterogeneity in acquisition protocols, medication status, and illness duration across contributing studies.

Study Type: First-in-human pilot trial (prospective, single-centre, uncontrolled)

Key Question: Can deep brain stimulation (DBS) targeting the nucleus accumbens safely and durably reduce severe self-injurious behaviour in children with profound autism?

Key Findings:

• Six participants (aged 7–14) underwent bilateral NAc-DBS with mean follow-up of 32.5 months; sustained reductions in SIB frequency/severity and repetitive behaviours were reported across the cohort
• One serious adverse event (device infection requiring explantation) caused relapse to baseline; re-implantation produced rapid SIB improvement, providing withdrawal-rechallenge evidence of treatment-specific effect
• Clinically meaningful quality-of-life improvements were reported over multi-year follow-up

Clinical Relevance: For UK clinicians managing treatment-refractory SIB in neurodevelopmental disorders — where pharmacological and behavioural options are often exhausted — this provides preliminary evidence that circuit-targeted neuromodulation warrants further investigation.

Limitations: Extremely small, uncontrolled sample (n=6) without a comparator group severely limits generalisability and causal inference at cohort level.

Study Type: Commentary/narrative review

Key Question: Does LC-NE system hyperactivity underlie neuropsychiatric symptoms in early Alzheimer's disease, and can it serve as a therapeutic target?

Key Findings:

• Neuropsychiatric symptoms (anxiety, agitation, depression, sleep disturbance) commonly precede cognitive decline in AD and are proposed to reflect LC-NE hyperactivity across amygdala, thalamus, hypothalamus, PFC, and anterior cingulate circuits
• Neuroimaging and physiological biomarkers now enable in vivo assessment of LC integrity and noradrenergic transmission, potentially allowing earlier detection of dysfunction
• Authors propose biomarker-driven, stage-specific pharmacological and neuromodulatory interventions targeting LC-NE tone to reduce NPS burden and augment disease-modifying therapies

Clinical Relevance: Psychiatrists managing dementia-related neuropsychiatric symptoms in NHS memory services may find noradrenergic targets relevant to treatment-refractory agitation, anxiety, and sleep disturbance where current options are limited.

Limitations: As a narrative review without systematic methodology, conclusions reflect authors' interpretive framing rather than synthesised evidence; no original data are presented.